BIRC5 and neoplasm: In the analysis of the iTAAs’ targeting binding locations and levels before and after HELC chemotherapy in the intranuclear regions of the tumor cells, the c-MYC (0.35%, 95% CI (0.033, 15.26) vs. 42.21%, 95% CI (15.53, 67.46)), IMP1 (0.01%, 95% CI (0.00, 2.76) vs. 26.34%, 95% CI (15.20, 47.39)) and Survivin (0.04%, 95% CI (0.00, 3.23) vs. 17.89%, 95% CI (16.07, 31.86)) proteins were significantly elevated (p = 0.02, p = 0.001, p < 0.0001) (Table 4, Figs. 6, 7, 8, 9, 10, 17, 18, 19, 20, 21, 22, 23).